Leber's disease with G3635A mutation

Article

In this article, the authors report on a case of two brothers with genetically proved Leber's disease associated with the rarer mutation G3635A, which is the only family case encountered in Bulgaria thus far.

The prevalence of Leber's disease is estimated at around 1/15000–1/50000 people. The clinical manifestation is acute or subacute, painless loss of central vision, which is usually persistant (with varying chance for recovery of vision depending on the mutation).

The most frequently found mutations in European patients are in the 3460, 11778 and 14484 nucleotides (associated with 90% of the cases). However, there are some other primary mutations, as well as secondary mutations that mostly affect the penetrance of the disease, which is incomplete in the LHON families - only 50% of men and 10% of women with the typical mtDNA mutations develop optic neuropathy.1–4

OCT: Valuable assessment

Some studies in LOHN have found that the fibres in the nasal quadrant show the lowest reduction, while the first and the most severely affected ones are the temporal segments, and that RNFL is thickened during the early stages of the optic neuropathy (duration of less than 6 months), while it shows thinning in the later, atrophic stages (more than 6 months).7

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.